PMID- 26942058
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 2162-4011 (Print)
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Linking)
VI  - 5
IP  - 1
DP  - 2016
TI  - T cell receptor mimic antibodies for cancer therapy.
PG  - e1049803
LID - e1049803
AB  - The major hurdle to the creation of cancer-specific monoclonal antibodies (mAb) 
      exhibiting limited cross-reactivity with healthy human cells is the paucity of 
      known tumor-specific or mutated protein epitopes expressed on the cancer cell 
      surface. Mutated and overexpressed oncoproteins are typically cytoplasmic or 
      nuclear. Cells can present peptides from these distinguishing proteins on their 
      cell surface in the context of human leukocyte antigen (HLA). T cell receptor 
      mimic (TCRm) mAb can be discovered that react specifically to these complexes, 
      allowing for selective targeting of cancer cells. The state-of-the-art for TCRm 
      and the challenges and opportunities are discussed. Several such TCRm are moving 
      toward clinical trials now.
FAU - Dubrovsky, Leonid
AU  - Dubrovsky L
AD  - Memorial Sloan Kettering Cancer Center ; New York, NY USA.
FAU - Dao, Tao
AU  - Dao T
AD  - Memorial Sloan Kettering Cancer Center ; New York, NY USA.
FAU - Gejman, Ron S
AU  - Gejman RS
AD  - Memorial Sloan Kettering Cancer Center ; New York, NY USA.
FAU - Brea, Elliott J
AU  - Brea EJ
AD  - Memorial Sloan Kettering Cancer Center ; New York, NY USA.
FAU - Chang, Aaron Y
AU  - Chang AY
AD  - Memorial Sloan Kettering Cancer Center ; New York, NY USA.
FAU - Oh, Claire Y
AU  - Oh CY
AD  - Memorial Sloan Kettering Cancer Center ; New York, NY USA.
FAU - Casey, Emily
AU  - Casey E
AD  - Memorial Sloan Kettering Cancer Center ; New York, NY USA.
FAU - Pankov, Dmitry
AU  - Pankov D
AD  - Memorial Sloan Kettering Cancer Center ; New York, NY USA.
FAU - Scheinberg, David A
AU  - Scheinberg DA
AD  - Memorial Sloan Kettering Cancer Center ; New York, NY USA.
LA  - eng
GR  - R01 CA055349/CA/NCI NIH HHS/United States
GR  - P01 CA023766/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - T32 GM007739/GM/NIGMS NIH HHS/United States
GR  - T32 CA062948/CA/NCI NIH HHS/United States
GR  - F30 CA200327/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150601
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
PMC - PMC4760335
OTO - NOTNLM
OT  - T cell receptor (TCR)
OT  - TCR like antibody
OT  - TCR mimic antibody
OT  - immunotherapy
OT  - monoclonal antibody
EDAT- 2016/03/05 06:00
MHDA- 2016/03/05 06:01
PMCR- 2016/06/01
CRDT- 2016/03/05 06:00
PHST- 2015/03/03 00:00 [received]
PHST- 2015/05/06 00:00 [accepted]
PHST- 2016/03/05 06:00 [entrez]
PHST- 2016/03/05 06:00 [pubmed]
PHST- 2016/03/05 06:01 [medline]
PHST- 2016/06/01 00:00 [pmc-release]
AID - 1049803 [pii]
AID - 10.1080/2162402X.2015.1049803 [doi]
PST - epublish
SO  - Oncoimmunology. 2015 Jun 1;5(1):e1049803. doi: 10.1080/2162402X.2015.1049803. 
      eCollection 2016.